Answers are grounded in this paper and cite their sources.
Summary As obesity continues to be a global health challenge presenting various negative impacts on health outcomes and healthcare costs, there is a growing need for pharmacological interventions to address the issue. Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes, but there is a lack of studies comparing adverse events across different populations. This review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals for treating overweight or obesity in adults, adolescents, and children.
No takes yet. Share an insight, caveat, or question.
Baden et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: